Presentation is loading. Please wait.

Presentation is loading. Please wait.

Therapeutic results of diffuse large B-cell lymphoma LNH 2008 Groupe d’Etude des Lymphomes en Tunisie Sousse, 25 th May 2012.

Published byThomasina Cooper Modified over 8 years ago

Similar presentations

Presentation on theme: "Therapeutic results of diffuse large B-cell lymphoma LNH 2008 Groupe d’Etude des Lymphomes en Tunisie Sousse, 25 th May 2012."— Presentation transcript:

1 Therapeutic results of diffuse large B-cell lymphoma LNH 2008 Groupe d’Etude des Lymphomes en Tunisie Sousse, 25 th May 2012

2 Introduction  LNH 2008: third protocol …after LNH 97 and LNH 2002  Between september 2008- august 2011

3 LNH 97 LNH 2002 aa-IPI=0, 16-65y 3CHOP+RT aa-IPI=0, 16-70y aa-IPI=1,2,3 16-55 4 ACVBP+conso aa-IPI=1, 16-60y 4 R-ACVBP+ Auto aa-IPI=2-3,16-60y aa-IPI=1,2,3, 56-65y 8 (R)-CHOP aa-IPI=1,2,3, 61-70y aa-IPI=0, > 65y 4 mini-CEOP+RT aa-IPI=0, > 70y aa-IPI=1,2,3, > 65y 6 CVP or 6 mini-CEOP aa-IPI=1,2,3, > 70y

4

5 LNH 2002 OS = 58%

6 LNH 2002-1 OS = 87 %

7 LNH 2002-2A OS = 82%

8 LNH 2002-2B OS = 46%

9 LNH 2002-3 OS = 52%

10 LNH 2002-5 OS = 38%

11 3 d prospective protocol LNH 2008 September 2008- August 2011 Oncology Tunis: 65 patients Hematology Tunis HO: 47 patients Oncology Sousse: 31 patients Hematology+Oncology Sfax: 27 patients Hematology Military: 22 patients Hematology Monastir: 20 patients Hematology Sousse: 17 patients CNGMO

12 LNH 2008 Risk Stratification aa- IPI aa- IPI 0 2008-1 2008-4 2008-4 1 2008-2A 2008-2A 2008-3 2008-3 2008-5 2008-5 2-3 2-3 2008-2B 2008-2B Age 60 y 70 y

13 LNH 2008 (16 - 70 y) B, 0 factor B, 1,2,3 factor(s) 16 - 59 y 60 - 70 y 16 - 59 y 60 - 70 y 2008-1 2008-2 2008-3 2008-1 2008-2 2008-3 6 R - CHOP 14 8 R-CHOP 14 8 R-CHOP 21 Prognostic Factors : LDH > 1N ; Stage III, IV ; PS > 2 1 factor 2-3 factors 2008-2A 2008-2B 4 R-ACVBP + PBSCT

14 LNH 2008 (> 70 y) Prognostic Factors : LDH > 1N ; Stage III, IV ; PS > 2 2008-4 2008-5 6 R-CHOP 21 6 mini CEOP B >75 y or B, 71-75 1,2,3 factor(s) B, 71-75 PS > 2, 1,2,3 factor(s) B, 71-75 y, PS<2 0, 1, 2 factor(s)

15 Patient’ characteristics  Age: 54 y (16-86y)  Gender: M: 136 sex-ratio: 1.46 F: 93  6 groups: LNH 2008-1: 60 patients LNH 2008-2A: 50 patients LNH 2008-2B: 51 patients LNH 2008-3: 23 patients LNH 2008-4: 13 patients LNH 2008-5: 32 patients

16 Sites at diagnosis Site of diagnosis (%) All12A2B345 Nodes 46245965265447 GIT 2232236262322 ORL 143226181512 Skin 32426 Others 1510122130813

17 Sites at diagnosis Site of diagnosis (%) All12A2B345 Nodes 46245965265447 GIT 2232236262322 ORL 143226181512 Skin 32426 Others 1510122130813

18 Sites at diagnosis Site of diagnosis (%) All12A2B345 Nodes 46245965265447 GIT 2232236262322 ORL 143226181512 Skin 32426 Others 1510122130813

19 Localisation (%) All12A2B345 Nodal352541 223140 Nodal + extra nodal 32181543484622 Extra nodal 33572416302338

20 Localisation (%) All12A2B345 Nodal352541 223140 Nodal + extra nodal 32181543484622 Extra nodal 33572416302338

21 Localisation (%) All12A2B345 Nodal352541 223140 Nodal + extra nodal 32181543484622 Extra nodal 33572416302338

22 Pronostic factors %All12A2B345 B41102878573853 ECOG 2-3 19023748041 LDH5005465703950 III-IV4804196706253 E57774451576250 Bulky16714414812

23 Pronostic factors %All12A2B345 B41102878573853 ECOG 2-3 19023748041 LDH5005465703950 III-IV4804196706253 E57774451576250 Bulky16714414812

24 Response %All12A2B345 CR75948254708466 PR63410906 Failure1331222121618 Death602169010

25 Response %All12A2B345 CR75948254708466 PR63410906 Failure1331222121618 Death602169010

26 Response %All12A2B345 CR75948254708466 PR63410906 Failure1331222121618 Death602169010

27 Response  LNH 2008-2B CR+PR: 32 patients Auto: 23 patients

28 Toxicity %All12A2B345 Time between cures 7978 747788 G-CSF4530528630466 Grade 3-4 164143822233 Death60216909

29 Toxicity %All12A2B345 Time between cures 7978 747788 G-CSF4530528630466 Grade 3-4 164143822233 Death60216909

30 Relapse (18 patients) All12A2B345 N%N% 18 10 2424 5 12 1414 3 19 4 36 3 14

31 Relapse (18 patients) All12A2B345 N%N% 18 10 2424 5 12 1414 3 19 4 36 3 14

32 Final Assessment (median follow-up:18 months) %All12A2B345 CR172927464614662 CR232648 Progression 434615 Death2131632353138

33 Final Assessment %All12A2B345 CR172927464614662 CR232648 Progression 434615 Death2131632353138

34 Final Assessment %All12A2B345 CR172927464614662 CR232648 Progression 434615 Death2131632353138

35 LNH 2008 OS = 75%

36 LNH 2008 EFS = 69%

37 LNH 2008-1 OS = 93%

38 LNH 2008-1 EFS = 90%

39 LNH 2008-2A OS = 79%

40 LNH 2008-2A EFS = 71%

41 LNH 2008-2B OS = 67%

42 LNH 2008-2B EFS = 59%

43 LNH 2008-3 OS = 62%

44 LNH 2008-3 EFS = 54%

45 LNH 2008-4 OS = 63%

46 LNH 2008-4 EFS = 41%

47 LNH 2008-5 OS = 56%

48 LNH 2008-5 EFS = 61%

49 Conclusions  LNH 2008-1: 6 R-CHOP14 is a good option (CHOP+RT)  LNH 2008-2A: 8 R-CHOP14 / 4 R-ACVBP+conso  LNH 2008-2B: 4 R-ACVBP  toxicity++ PBSCT is the standard  LNH 2008-3: 8 R-CHOP 21 +++  LNH 2008-4: testing for treatment of elderly patients with CHOP (EFS < 2008-5)  LNH 2008-5: 6 R-miniCEOP

50 ACKNOWLEDGEMENTS All the members of GELT Ben Lakhal Raihane Ben Othman Tarek Elloumi Moez Gharbi Olfa Mezlini Amel Msadek Fehmi Toumi Nabil Zahra Kmira Laatiri M. Adnène

Download ppt "Therapeutic results of diffuse large B-cell lymphoma LNH 2008 Groupe d’Etude des Lymphomes en Tunisie Sousse, 25 th May 2012."

Similar presentations

Non Hodgkin’s lymphoma

Non Hodgkin’s lymphoma
Follicular lymphoma Optimal primary therapy and consolidation ? Seminars in Hematological Oncology * Israel, April 26 2007 M. Dreyling, Dept. of Medicine.

Follicular lymphoma Optimal primary therapy and consolidation ? Seminars in Hematological Oncology * Israel, April M. Dreyling, Dept. of Medicine.
1. DLBCL of the elderly in age older than life expectancy the single institute experience in Taiwan Sheng Hsuan,Chien, MD Division of Hematology and Oncology,

1. DLBCL of the elderly in age older than life expectancy the single institute experience in Taiwan Sheng Hsuan,Chien, MD Division of Hematology and Oncology,
Casulo C et al. Proc ASH 2013;Abstract 510.

Casulo C et al. Proc ASH 2013;Abstract 510.
CORAL: COllaborative trial in Relapsed Aggressive Lymphoma R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed.

CORAL: COllaborative trial in Relapsed Aggressive Lymphoma R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed.
M. BENDARI, M. Rachid, S. Marouane, A. Quessar, S. Benchekroun Department of Hematology-Oncology pediatric Hospital 20 Aout, CHU Ibn Rochd Casablanca.

M. BENDARI, M. Rachid, S. Marouane, A. Quessar, S. Benchekroun Department of Hematology-Oncology pediatric Hospital 20 Aout, CHU Ibn Rochd Casablanca.
Jonathan W. Friedberg M.D., M.M.Sc. University of Rochester Medical Center Optimal frontline therapy for Follicular lymphoma: Do we need to start with.

Jonathan W. Friedberg M.D., M.M.Sc. University of Rochester Medical Center Optimal frontline therapy for Follicular lymphoma: Do we need to start with.
Hematopoietic Stem Cell Transplantation: High Risk Diffuse Large Cell Lymphoma: Ginna G. Laport, MD Associate Professor of Medicine Division of Blood &

Hematopoietic Stem Cell Transplantation: High Risk Diffuse Large Cell Lymphoma: Ginna G. Laport, MD Associate Professor of Medicine Division of Blood &
Rituximab Maintenance: Stage III/IV Follicular Lymphoma (ECOG/CALGB E1496) Subset: 237 FL pts CVP x 6-8 → PR/CR (cyclophosphamide, vincristine, prednisone)

Rituximab Maintenance: Stage III/IV Follicular Lymphoma (ECOG/CALGB E1496) Subset: 237 FL pts CVP x 6-8 → PR/CR (cyclophosphamide, vincristine, prednisone)
Eastern cooperative oncology group E1496: ECOG and CALGB Cyclophosphamide/Fludarabine (CF) with or without Maintenance Rituximab (MR) in Advanced Indolent.

Eastern cooperative oncology group E1496: ECOG and CALGB Cyclophosphamide/Fludarabine (CF) with or without Maintenance Rituximab (MR) in Advanced Indolent.
MabThera ® and Autologous Stem Cell Transplant (ASCT)

MabThera ® and Autologous Stem Cell Transplant (ASCT)
Neue Perspektiven in der Therapie Follikulärer Lymphome.

Neue Perspektiven in der Therapie Follikulärer Lymphome.
Treatment of Non- Hodgkin’s Lymphoma. Precursor B cell Lymphoblastic Leukemia Remission induction with combination therapy Consolidation phase: –High.

Treatment of Non- Hodgkin’s Lymphoma. Precursor B cell Lymphoblastic Leukemia Remission induction with combination therapy Consolidation phase: –High.
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma Luigi Marcheselli, Raffaella Marcheselli, Alessia Bari, Eliana.

Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma Luigi Marcheselli, Raffaella Marcheselli, Alessia Bari, Eliana.
MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.

MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.
Background Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoma in the Western world. It’s account for about one-third of all.

Background Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoma in the Western world. It’s account for about one-third of all.
FC and FCR in CLL and Indolent NHL: A descriptive retrospective institutional study Aftimos P, Chahine G Hotel-Dieu de France University Hospital Beirut,

FC and FCR in CLL and Indolent NHL: A descriptive retrospective institutional study Aftimos P, Chahine G Hotel-Dieu de France University Hospital Beirut,
Rituximab efficacy in other haematological malignancies Christian Buske.

Rituximab efficacy in other haematological malignancies Christian Buske.
R-CHOP vs R-FC Followed by Maintenance with Rituximab vs Interferon-Alfa in Elderly Patients with Mantle Cell Lymphoma Kluin-Nelemans HC et al. Proc ASH.

R-CHOP vs R-FC Followed by Maintenance with Rituximab vs Interferon-Alfa in Elderly Patients with Mantle Cell Lymphoma Kluin-Nelemans HC et al. Proc ASH.
NHL13: A Multicenter, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation Alone in Patients with Aggressive B ‐ Cell Lymphoma.

NHL13: A Multicenter, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation Alone in Patients with Aggressive B ‐ Cell Lymphoma.

Similar presentations

Ads by Google